The global morphine drugs market size was estimated to be USD 23.91 billion in 2023 and is expected to reach USD 39.79 billion by 2034 with a CAGR of 4.74% during the forecast period 2024-2034. The factors that will drive the market growth are the rising prevalence of chronic pain, cancer incidence, surgical procedures, trauma cases, increased awareness of pain management, technological advancements in drug delivery systems, expanding government initiatives, and partnerships and collaborations.
The demand for morphine medications is largely driven by chronic pain problems, including pain from cancer and pain following surgery. Effective pain management drugs are increasingly needed as the world's population ages and chronic pain becomes more common. An increase in the prescription and usage of morphine medications in suitable clinical settings has resulted in patients and healthcare professionals' growing understanding of the significance of efficient pain treatment. For instance, a report published by the MDPI in May 2021 found that chronic pain was a significant problem impacting over 50% of the elderly population.
By dosage form, the injection segment accounted for the highest revenue-grossing segment in the global morphine drugs market in 2023 owing to the growing preference for fast-acting and precise pain management solutions in acute healthcare settings, increased adoption of injectable morphine formulations in post-surgical care, and the rising prevalence of severe pain conditions requiring immediate relief. For instance, in May 2022, researchers from Oklahoma State University Center for Health Sciences and the University of Arizona Health Sciences formed a novel collaboration to address the opioid issue and find and create cutting-edge treatments for the management of chronic pain. Additionally, the oral tablets segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend of outpatient pain management, increased patient preference for oral medications for long-term pain relief, and continuous efforts by pharmaceutical companies to develop innovative and patient-friendly oral tablet formulations of morphine.
By application, the pain management segment accounted for the highest revenue-grossing segment in the global morphine drugs market in 2023 owing to the growing prevalence of chronic pain conditions, increased awareness and emphasis on comprehensive pain management across various healthcare settings, and the expanding patient pool seeking effective analgesic solutions. For instance, a study published in January 2022 by the National Library of Medicine claims that several opioids such as remifentanil, morphine, and fentanyl were utilized to treat chronic pain during the COVID-19 epidemic. Additionally, the other applications segment is predicted to grow at the fastest CAGR during the forecast period owing to the diversification of morphine drug applications, with emerging therapeutic uses beyond traditional pain management, including potential applications in psychiatric and neurological disorders.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global morphine drugs market in 2023 owing to the increasing volume of morphine prescriptions for inpatient care, a surge in surgical procedures requiring postoperative pain management, and the central role of hospital pharmacies in dispensing medications for acute and chronic conditions. For instance, in July 2022, Bryant Ranch Prepack Inc. voluntarily recalled one lot of 30 mg and one lot of 60 mg extended-release morphine sulfate tablets from consumers. Each lot included ten bottles. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of digital health platforms, increased consumer convenience, and a growing trend towards online purchasing of pharmaceuticals.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust healthcare infrastructure, a high prevalence of chronic pain conditions, advanced medical research and development initiatives, and a strong emphasis on pain management protocols. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of pain management, a growing geriatric population, increasing spending on healthcare and expanding access to services. For instance, Mylan N.V. announced in 2023 that it is collaborating with Hikma Pharmaceuticals to broaden their offering in pain management in the Middle East and North Africa.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The demand for morphine medications is largely driven by chronic pain problems, including pain from cancer and pain following surgery. Effective pain management drugs are increasingly needed as the world's population ages and chronic pain becomes more common. An increase in the prescription and usage of morphine medications in suitable clinical settings has resulted in patients and healthcare professionals' growing understanding of the significance of efficient pain treatment. For instance, a report published by the MDPI in May 2021 found that chronic pain was a significant problem impacting over 50% of the elderly population.
By dosage form, the injection segment accounted for the highest revenue-grossing segment in the global morphine drugs market in 2023 owing to the growing preference for fast-acting and precise pain management solutions in acute healthcare settings, increased adoption of injectable morphine formulations in post-surgical care, and the rising prevalence of severe pain conditions requiring immediate relief. For instance, in May 2022, researchers from Oklahoma State University Center for Health Sciences and the University of Arizona Health Sciences formed a novel collaboration to address the opioid issue and find and create cutting-edge treatments for the management of chronic pain. Additionally, the oral tablets segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend of outpatient pain management, increased patient preference for oral medications for long-term pain relief, and continuous efforts by pharmaceutical companies to develop innovative and patient-friendly oral tablet formulations of morphine.
By application, the pain management segment accounted for the highest revenue-grossing segment in the global morphine drugs market in 2023 owing to the growing prevalence of chronic pain conditions, increased awareness and emphasis on comprehensive pain management across various healthcare settings, and the expanding patient pool seeking effective analgesic solutions. For instance, a study published in January 2022 by the National Library of Medicine claims that several opioids such as remifentanil, morphine, and fentanyl were utilized to treat chronic pain during the COVID-19 epidemic. Additionally, the other applications segment is predicted to grow at the fastest CAGR during the forecast period owing to the diversification of morphine drug applications, with emerging therapeutic uses beyond traditional pain management, including potential applications in psychiatric and neurological disorders.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global morphine drugs market in 2023 owing to the increasing volume of morphine prescriptions for inpatient care, a surge in surgical procedures requiring postoperative pain management, and the central role of hospital pharmacies in dispensing medications for acute and chronic conditions. For instance, in July 2022, Bryant Ranch Prepack Inc. voluntarily recalled one lot of 30 mg and one lot of 60 mg extended-release morphine sulfate tablets from consumers. Each lot included ten bottles. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of digital health platforms, increased consumer convenience, and a growing trend towards online purchasing of pharmaceuticals.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust healthcare infrastructure, a high prevalence of chronic pain conditions, advanced medical research and development initiatives, and a strong emphasis on pain management protocols. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of pain management, a growing geriatric population, increasing spending on healthcare and expanding access to services. For instance, Mylan N.V. announced in 2023 that it is collaborating with Hikma Pharmaceuticals to broaden their offering in pain management in the Middle East and North Africa.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Dosage Form, Application, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Morphine Drugs Market Report 2023 - 2034
Morphine Drugs Market Analysis & Forecast by Dosage Form 2023 - 2034 (Revenue USD Bn)
- Injection
- Oral
- Other
Morphine Drugs Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Pain Management
- Diarrhea Suppressant
- Cold & Cough Suppressant
- Others
Morphine Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Morphine Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Morphine Drugs Market: Dosage Form Estimates & Trend Analysis
8. Morphine Drugs Market: Application Estimates & Trend Analysis
9. Morphine Drugs Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Morphine Drugs Market
12. Europe Morphine Drugs Market
13. Asia Pacific Morphine Drugs Market
14. Latin America Morphine Drugs Market
15. MEA Morphine Drugs Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Purdue Pharma
- Mallinckrodt Pharmaceuticals
- Johnson & Johnson
- Endo Pharmaceuticals
- Mundipharma
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Boehringer Ingelheim
- Grünenthal Group
- Sun Pharmaceutical Industries Ltd.
- Sanofi
- Indivior PLC
- Rhodes Pharmaceuticals L.P.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 23.91 Billion |
| Forecasted Market Value ( USD | $ 39.79 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
